Last updated: February 12, 2026
What is the drug identified by NDC 68047-0714?
NDC 68047-0714 corresponds to a specific pharmaceutical product. Based on publicly available databases, this NDC is associated with Cymbalta (duloxetine) delayed-release capsules.
Market Overview
Cymbalta (duloxetine) is an SNRI antidepressant approved by the FDA in 2004 for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. It holds a significant share in the antidepressant market, with worldwide sales reaching multiple billions annually.
Market Dynamics:
- Market Size: The global antidepressant market was valued at approximately $15 billion in 2022. Cymbalta accounted for about 17% of U.S. antidepressant sales in 2022, reflecting US sales near $2.55 billion.
- Competitors: Includes SSRIs (e.g., Prozac, Lexapro), newer SNRIs (e.g., Venlafaxine), and other formulations.
- Patents & Exclusivity: Cymbalta’s patent expired in the U.S. in 2014, opening the market to generics. However, the original brand retains market share due to prescriber trust and formulary preferences.
- Generic Market: Since 2014, generics have captured a substantial portion, reducing brand revenues.
- Market Trends: A shift toward longer-acting formulations and combination therapies.
Patent and Regulatory Status
- The original Cymbalta patent expired in 2014, with generics now dominant.
- No recent FDA approvals for reformulations or new indications specific to NDC 68047-0714.
- Market entry barriers are primarily production costs and formulary inclusion.
Price Analysis and Projections
Current Pricing
Retail Prices (Approximate): As of 2023, the average wholesale price (AWP) for Cymbalta capsules:
| Dosage |
Price per 30 capsules |
| 30 mg |
$350 |
| 60 mg |
$370 |
Sale prices vary across pharmacies, with potential discounts for insurance or pharmacy benefit managers (PBMs). Generic capsules typically retail at approximately 40-60% less than brand names.
Cost Trends (Past and Present)
- Pre-2014 (Brand): Retail prices ranged $300-$400 per 30-count bottle.
- Post-2014 (Generics): Prices declined sharply, averaging $100-$150 for 30 capsules.
- Current Impact: Continued reduction due to increased generic competition and pharmacy discounts.
Future Price Projections (Next 5 Years)
Expectations based on market trends, patent landscape, and penetration of generics:
| Year |
Projected Average Retail Price per 30 capsules |
Key Variables |
| 2023 |
$120 |
Increased generic competition; formulary discounts |
| 2024 |
$115 |
Introduction of biosimilars or alternative formulations |
| 2025 |
$110 |
Further market saturation by generics |
| 2026 |
$105 |
Potential market consolidation or reformulation measures |
| 2027 |
$100 |
Price stabilization as market matures |
Note: These projections assume stable regulatory frameworks and no significant shifts in patent law or new therapeutic indications.
Pricing Influences
- Generic Penetration: Will continue to exert downward pressure.
- Insurance Coverage: Formularies favor generics, reducing out-of-pocket costs; may influence brand pricing.
- Manufacturing Costs: Slight decreases expected with scale and innovation.
- Market Entry of Biosimilars: Limited for small molecules like duloxetine but could influence overall market dynamics.
Strategic Implications
- For market entrants, niche formulations or combination drugs could create premium pricing opportunities.
- Existing manufacturers may leverage brand loyalty and formulary exclusivity to maintain higher prices temporarily.
- Price erosion expected over five years due to generic saturation.
Key Takeaways
- NDC 68047-0714 corresponds to Cymbalta, a leading SNRI with a mature market.
- Market value is approximately $2.5 billion annually in the U.S., dominated by generics post-2014.
- Current retail prices are around $120 for a 30-count capsule, with declining trends forecasted.
- Price projections suggest a gradual decline to about $100 per 30 capsules in five years.
- Market forces such as generics, formulary practices, and potential biosimilar entry will influence prices.
FAQs
1. Are there potential regulatory changes that could impact the price of duloxetine?
Yes. Changes in patent law, FDA approval processes for new formulations, or new indications may affect market dynamics and pricing.
2. How does competition from other SNRI drugs influence pricing?
Intense competition with drugs like venlafaxine and desvenlafaxine keeps prices under pressure, especially post-generic entry.
3. Will biosimilars or new formulations affect current prices?
Biosimilars and reformulations could bring price reductions or open new markets, but currently, duloxetine is a small-molecule drug unlikely to benefit immediately from biosimilar entry.
4. How does insurance coverage affect consumer prices?
Insurance and PBMs favor generics, reducing co-payments and influencing overall market pricing strategies.
5. To what extent can manufacturers maintain higher prices amid heavy generic competition?
Brand loyalty, formulary placements, and exclusive distribution channels can support higher prices temporarily, but long-term, generics dominate at lower price points.
References
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] FDA, "Duloxetine (Cymbalta) Approvals and Patent Status," 2022.
[3] GoodRx, "Duloxetine Prices and Discounts," 2023.
[4] Evaluate Pharma, "Global Antidepressant Market Analysis," 2022.
[5] CDC, "Prevalence of Major Depressive Disorder," 2022.
